What is the recommended therapy for gastroesophageal reflux disease (GERD) in adults?

GERD Therapy

First-Line Treatment: Proton Pump Inhibitors

Proton pump inhibitors (PPIs) are the most effective first-line pharmacological treatment for GERD, superior to H2-receptor antagonists and antacids for both symptom relief and esophagitis healing. 1, 2, 3

Initial PPI Regimen

• Start with omeprazole 20 mg or lansoprazole 30 mg once daily, taken 30–60 minutes before breakfast for an initial 4–8 week trial 1, 2, 3
• Empiric PPI therapy is appropriate for patients with typical heartburn or regurgitation without alarm features (dysphagia, weight loss, anemia, bleeding, recurrent vomiting) and does not require initial endoscopy 1, 2, 4
• Assess response at 4–8 weeks 1, 2

Treatment Escalation for Persistent Symptoms

• If symptoms persist after 4 weeks of standard once-daily dosing, increase to twice-daily PPI (one dose 30–60 minutes before breakfast, one before dinner) for an additional 4–8 weeks 1, 2, 3
• Alternatively, switch to a more potent PPI such as esomeprazole 40 mg or rabeprazole 20 mg 1, 2
• Do not add a nocturnal H2-receptor antagonist to twice-daily PPI therapy—this combination provides no additional benefit and tachyphylaxis develops within approximately 6 weeks 1, 2

---

Essential Lifestyle Modifications

Weight loss is the single most effective lifestyle intervention for GERD (Grade B evidence), particularly for patients with BMI ≥ 25 kg/m² 1, 2, 3

Evidence-Based Lifestyle Measures

• Elevate the head of the bed by 6–8 inches (15–20 cm) using blocks or a wedge for patients with nocturnal symptoms or regurgitation 1, 2, 3
• Avoid lying down for 2–3 hours after meals to reduce esophageal acid exposure 1, 2, 3
• Identify and avoid individual trigger foods through detailed dietary history rather than imposing broad restrictions; common triggers include coffee, chocolate, alcohol, spicy foods, citrus, tomatoes, and high-fat meals 1, 2
• Limit dietary fat intake to ≤45 grams per day, as high-fat meals delay gastric emptying and increase reflux 1, 2
• Smoking cessation and alcohol limitation are recommended, as both worsen GERD symptoms 2, 4

---

Adjunctive Pharmacotherapy: Personalized to GERD Phenotype

Adjunctive agents should be personalized to the specific GERD phenotype rather than used empirically. 1, 5

Phenotype-Specific Adjuncts

• Alginate-containing antacids (e.g., Gaviscon 10–20 mL after meals and at bedtime) for breakthrough symptoms, post-prandial symptoms, or patients with hiatal hernia—the alginate "raft" neutralizes the post-prandial acid pocket 1, 5
• Nighttime H2-receptor antagonists (e.g., famotidine 20 mg at bedtime) for persistent nocturnal symptoms despite PPI therapy, though tachyphylaxis may develop 1, 6
• Baclofen (5–10 mg three times daily, titrated to 20 mg three times daily as tolerated) for regurgitation-predominant or belch-predominant symptoms—reduces transient lower esophageal sphincter relaxations 1, 2
• Prokinetic agents for coexistent gastroparesis symptoms, though metoclopramide should be avoided due to risk of tardive dyskinesia and unfavorable risk-benefit profile (Grade D recommendation) 1, 2

---

Diagnostic Evaluation for Refractory GERD

Perform upper endoscopy after 8–12 weeks of optimized twice-daily PPI therapy if symptoms persist, to assess for erosive esophagitis (Los Angeles grade B or higher), Barrett's esophagus, strictures, eosinophilic esophagitis, or alternative diagnoses 1, 2, 6

Diagnostic Algorithm for Persistent Symptoms

• Endoscopy is indicated upfront when alarm features are present (dysphagia, weight loss, anemia, bleeding, family history of upper GI cancer in multiple first-degree relatives) 1, 2, 6
• If endoscopy is normal but symptoms continue, perform 24-hour pH-impedance monitoring off PPI (withhold therapy for 2–4 weeks) to confirm GERD diagnosis, detect non-acid reflux, and assess symptom-reflux correlation 1, 2, 6
• High-resolution esophageal manometry is recommended before considering surgical or endoscopic intervention to exclude achalasia and assess peristaltic function 1, 7

---

Special Considerations: Extra-Esophageal GERD Symptoms

For patients with extra-esophageal manifestations (chronic cough, laryngitis, globus sensation, asthma), initiate twice-daily PPI dosing from the outset and continue for a minimum of 8–12 weeks before assessing response. 1, 2

Management of Extra-Esophageal Symptoms

• Extra-esophageal symptoms require more intensive and prolonged therapy than typical heartburn, with lower response rates 1, 2
• Implement a strict antireflux diet (≤45 g fat per day, eliminate coffee, tea, soda, chocolate, mints, citrus, alcohol) 1, 2
• Allow a full 8–12 weeks of optimized therapy before concluding treatment failure 1, 2
• If symptoms persist after 3 months of intensive medical therapy, proceed with objective testing (24-hour pH monitoring, endoscopy) to determine if acid suppression is adequate or if medical therapy has failed 1, 2

---

Long-Term Management and PPI De-Escalation

Once symptom control is achieved, taper the PPI to the lowest effective dose that maintains relief. 1, 2, 3

Maintenance Strategy

• For patients without endoscopically confirmed erosive esophagitis or Barrett's esophagus, consider gradual dose reduction or on-demand PPI therapy once symptoms are stable 1, 2
• If PPI therapy extends beyond 12 months without objective confirmation of GERD, offer repeat endoscopy with prolonged pH monitoring to reassess the need for continued therapy 1, 2
• For patients with confirmed erosive esophagitis (Los Angeles grade B or higher) or Barrett's esophagus, long-term PPI therapy is generally required and benefits outweigh risks 2, 3
• Periodically reassess the need for continued PPI therapy to minimize potential long-term risks (community-acquired pneumonia, Clostridioides difficile infection, bone fractures, vitamin B12 deficiency, hypomagnesemia, chronic kidney disease) 1, 2

---

Surgical and Endoscopic Interventions

Laparoscopic fundoplication and magnetic sphincter augmentation are effective surgical options for carefully selected patients with proven GERD. 1, 7

Candidacy Criteria for Anti-Reflux Surgery

Surgery is indicated only when all of the following criteria are met: 1, 7

• Failure of at least 3 months of intensive medical therapy (twice-daily PPI plus lifestyle measures)
• Objective documentation of pathological GERD (erosive esophagitis on endoscopy or abnormal acid exposure on off-PPI pH monitoring)
• Positive symptom-reflux correlation on pH-impedance testing
• Preserved esophageal peristalsis on high-resolution manometry (to exclude achalasia)
• Significant impairment of health-related quality of life

Surgical Options

• Laparoscopic fundoplication (partial fundoplication preferred when esophageal hypomotility is present) yields durable symptom remission in properly selected patients 1, 7
• Magnetic sphincter augmentation combined with crural repair is appropriate for patients with hiatal hernia 1, 7
• Transoral incisionless fundoplication (TIF 2.0) is an endoscopic option for carefully selected patients without hiatal hernia 1, 7
• Roux-en-Y gastric bypass is an effective primary anti-reflux intervention in obese patients (BMI ≥ 35 kg/m²) and a salvage option in non-obese patients, whereas sleeve gastrectomy has potential to worsen GERD 1, 7

---

Neuromodulation for Functional Heartburn and Reflux Hypersensitivity

For patients with esophageal hypersensitivity (normal acid exposure but positive symptom-reflux correlation), add low-dose tricyclic antidepressants (e.g., amitriptyline 10 mg or nortriptyline 10 mg at bedtime, titrated to 25–50 mg as tolerated) 1, 2

• Neuromodulator therapy is specifically recommended by the British Society of Gastroenterology for patients with esophageal hypersensitivity identified on pH-impedance testing 2
• Referral to a behavioral therapist for hypnotherapy, cognitive behavioral therapy, diaphragmatic breathing, and relaxation strategies is recommended for patients with functional heartburn or reflux hypersensitivity 1

---

Common Pitfalls to Avoid

• Do not use metoclopramide as monotherapy or adjunctive therapy for GERD due to risk of tardive dyskinesia (Grade D recommendation) 1, 2
• Do not add nocturnal H2-receptor antagonists to twice-daily PPI as standard practice—no evidence of improved efficacy and tachyphylaxis develops 1, 2
• Do not continue empiric PPI therapy indefinitely without objective testing if symptoms persist beyond 3 months of optimized treatment 1, 2
• Do not assume normal endoscopy rules out GERD as the cause of extra-esophageal symptoms—pH-impedance monitoring is required 1, 2
• Do not broadly recommend all lifestyle modifications to every GERD patient—evidence does not support this approach and leads to poor compliance; instead, target individual triggers 1, 2